Cell Banking Outsourcing Market 2021 By Size, Key Players Profile, In-Depth Qualitative Insights, Future Plans, COVID-19 Market Outlook, Industry…

Global Cell Banking Outsourcing Market is valued at USD 7122.6 Million in 2019 and expected to reach USD 18489.6 Million by 2026 with the CAGR of 14.6% over the forecast period.

Rising prevalence of cancer and infectious chronic disorders couples with growing demand for research and development in therapy viral cell banking and viral cell banking safety testing are expected to propel the growth of the Global Cell Banking Outsourcing Market.

Get Sample Copy of The Report@https://brandessenceresearch.com/requestSample/PostId/993

**Samplepagesforthisreportare immediatelyaccessibleuponrequest.**

The cell banking outsourcing is an ability that stores cells of specific genome for the purpose of future use in a product or medicinal needs to use of gene therapy, stem cell therapy, biopharmaceutical production that target on novel active sites. They are frequently containing expansive amounts of base cell material that can be utilized for various projects. The cell banking outsourcing can be used to generate detailed characterizations of cell lines and can also help mitigate cross-contamination of a cell line. Hence, the cell banking outsourcing is commonly used within fields including stem cell research and pharmaceuticals with cryopreservation being the traditional method of keeping cellular material intact. However, the cell banking is most generally used in stem cell research and therapy. The similar types of cell banking include master cell banks and working cell banks. Although, the master cell banks are expanded to form working cell banks consist of pure cells from are replicated whereas working cell banks consist of thawed cells that are replicated in cell culture.

Additionally, it is a process of replicating and storing cells for the purpose of future use. This storage of these cell samples can be utilized for research purposes and for surgical reconstruction of damaged body structures. However, the bank storage in cell banking encompasses preservation of both master and working cell banking, and their respective safety testing. The cell banking outsourcing expected to witness lucrative growth over the forecast period owing to the presence of increased research in cell line development coupled with the presence of market players providing outsourcing services for cell banking and cell line storage to different hospitals and clinical research organizations.

Global Cell Banking Outsourcing Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global cell banking outsourcing market is classified as the master cell banking, viral cell banking and working cell banking. Based upon application, global cell banking outsourcing is classified into bank storage, working cell bank storage, master cell bank storage cell storage stability testing, bank preparation, bank characterization & testing and others.

The regions covered in this cell banking outsourcing market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of cell banking outsourcing is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Some major key players for Global Cell Banking Outsourcing Market are,

Get Methodology Of The Report @https://brandessenceresearch.com/requestMethodology/PostId/993

Global Cell Banking Outsourcing Market Dynamics

The rapidly increasing awareness for stem cell banking in the developing countries, and increasing governments initiatives that promote awareness for stem cell isolation and related benefits are some of the major factors driving the market growth during the forecast period. In addition, increasing application of stem cells for developing personalized medicines to minimize the spread of various chronic diseases and also the association of aging with the inability of the body to maintain tissue turnover and hemostasis has helped researchers to focus on this target population for providing relative therapies that would act effectively on the damaged cells. These factors are also supplementing the market growth. According to the World Health Organization (WHO), estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 globes about 18.1 million new cancer cases about 17.0 million excluding no melanoma skin cancer and 9.6 million cancer deaths in 2018. Furthermore, the master cell banks are useful for the preparation of working cell banks and thus find applicability in various research and development perspectives for stem cell therapy and gene therapy thereby resulting to section growth. The occurrence of favorable government initiatives pertaining to the R&D for development of stable cell lines, the opening of new technology for storage and description of cell lines are among the critical factors predictable to advance market growth over the forecast period.

However, the high cost associated with storing these cells in cell banks is a major challenge faced by this market which may hamper the growth of cell banking outsourcing market. In addition, the various legal challenges associate with banking a variety of cells, especially considering stem cells banking, are expected to restrain market growth. The advanced technologically cryopreservation techniques are expected to fuel the growth of this market throughout the forecast period. In spite of that, the increase in the average life expectations due to advanced medical research and improved general lifestyle of the population and straightforward regulations for the stem cell researchers are expected to create significant potential for this market in coming few years. Increasing number of adipose tissue banking can offer various opportunities of the cell banking outsourcing market.

Global Cell Banking Outsourcing Market Regional Analysis

North America is expected to dominate the global cell banking outsourcing drug market due to the highest market share owing to the increasing number biopharmaceutical companies & manufacturers and increasing awareness for the use of stem cells as therapeutic proteins and antibiotics in this region. According to the World Health Organization (WHO), the American Cancer Society epidemiologists, at least 42% of newly diagnosed cancers in the U.S. about 729,000 cases are potentially avoidable, including 19% that are caused by smoking and 18% that are caused by a combination of excess body weight, physical inactivity, excess alcohol consumption, and poor nutrition. In addition, presence of regulatory authorities that promotes continuous R&D activities is also supplementing the market growth in North America.

The Asia Pacific is expected to witness significant growth in demand over the forecast period owing to increase in number of supportive government initiatives pertaining to investments in biotechnology sector in this region. In addition, the ongoing R&D activities for cancer treatment and fertility preservation facilitate the demand for cell banking services in this region.

Key Benefits for Global Cell Banking Outsourcing Market Report

Global Cell Banking Outsourcing Market report covers in depth historical and forecast analysis.

Global Cell Banking Outsourcing Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Cell Banking Outsourcing Market report helps to identify opportunities in market place.

Global Cell Banking Outsourcing Market report covers extensive analysis of emerging trends and competitive landscape.

By Type: Master Cell Banking, Viral Cell Banking, Working Cell Banking

By Application: Bank Storage, Working Cell Bank Storage, Master Cell Bank Storage, Cell Storage Stability Testing, Bank Preparation, Bank Characterization & Testing

Regional & Country AnalysisNorth America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Table of Content

1.1. Research Process

1.2. Primary Research

1.3. Secondary Research

1.4. Market Size Estimates

1.5. Data Triangulation

1.6. Forecast Model

1.7. USPs of Report

1.8. Report Description

2.1. Market Introduction

2.2. Executive Summary

2.3. Global Cell Banking Outsourcing Market Classification

2.4. Market Drivers

2.5. Market Restraints

2.6. Market Opportunity

2.7. Cell Banking Outsourcing Market: Trends

2.8. Porters Five Forces Analysis

2.9. Market Attractiveness Analysis

Get Full Report :@https://brandessenceresearch.com/healthcare/cell-banking-outsourcing-market-size

Go here to read the rest:

Cell Banking Outsourcing Market 2021 By Size, Key Players Profile, In-Depth Qualitative Insights, Future Plans, COVID-19 Market Outlook, Industry...

Read more
Dynamic Stem Cell Therapy Offers Regenerative Medicine – Las Vegas Review-Journal

Dynamic Stem Cell Therapy offers regenerative medicine

A serious car accident left Mike Licata with a debilitating injury to his left shoulder.

My injury was so severe, and the pain was unbelievably intense, Licata said. It interfered with every part of my life.

Looking for alternatives to invasive surgery, Licata discovered Dynamic Stem Cell Therapy.

Traditional surgery was going to be around $75,000, with three months in a cast, a year-plus of rehab, and probably $120,000 out of pocket, Licata said. I was in trouble, then a friend told me about stem cell therapy.

Dynamic Stem Cell Therapy specializes in regenerative medicine, using stem cells to initiate healing within the body.

Stem cells are the building blocks of the human body, Dynamic Co-founder and Chief Executive Officer Blake Youmans said. They act as a booster of healthy cells for the body to heal itself. When were giving this therapy, its to potentially reverse the trauma that has been sustained. Its basically to help give patients a better quality of life.

Licatas treatment involved a quick injection of his own stem cells into the injury site, harvested from his fat tissue through syringe aspirated mini liposuction. The entire procedure took approximately four hours from Licata entering the clinic.

They did their magic, Licata said. This was so easy. It doesnt compare to invasive surgery.

Within months of the stem cell therapy, Licatas shoulder was completely healed, and his quality of life was restored.

Now, its better than my other shoulder, Licata said. I cant tell you how much this has changed my life.

Licata is one of thousands of patients discovering regenerative medicine at Dynamic Stem Cell Therapy.

The revolutionary regenerative technique works for a variety of conditions and diseases.

We focus mainly on athletic trauma, Youmans said. And inflammatory diseases, such as arthritis and rheumatoid arthritis but it is a way to fix the entire body.

The minimally invasive procedure offers patients an alternative to surgery. Youmans noted his procedure is safe and effective with no reported side effects, and his patients notice a difference in as little as two weeks or up to only six months after injection.

Its really up to a patients own body to heal themselves, Youmans said. Its a great alternative to try before surgery.

The staff at Dynamic obtain stems cells from two different sources: in the office from a patients own fat cells through mini liposuction or from the donated umbilical cord of a newborn. Young mothers, between the ages of 18 and 35 are prescreened and provide authorization for the collection. A lab collects the umbilical cord after birth, and its stem cells are harvested and sold.

After age 65, our stem cell count goes way down, Youmans said. So, for older patients, I tell them it may be more effective to use zero-age stem cells for specific conditions.

Dynamic Stem Cell Therapy clinic has performed over 1,000 procedures over the last seven years. The success rate for patient outcomes averages from 75 to 100 percent.

Weve seen 98 percent success with knees, Youmans said. I feel good about what were doing helping patients get the results they want.

Regenerative medicine is successful in most patients, but the therapy has no guarantee of success. According to Youmans, all patients are thoroughly informed about that possibility before the therapy.

Ill bend over backward to make sure a patient gets a great result, Youmans said. But we cant guarantee anything or promise fast results.

The average cost of the treatment is $5,000 and is not covered by insurance. This price can still save patients thousands of dollars compared to surgery and follow-up rehabilitation.

Founded by Blake Youmans late mother, Simong Youmans, M.D. (an experienced Board- Certified Emergency Medicine Physician), Dynamic Stem Cell Therapy opened its doors in 2014.

Dr. Simong Youmans passion for helping people heal naturally, and, strengthening the bodys own defenses, led her to open several evidence-based alternative medicine businesses over the years. They include Elite Medical Services & Spa. Laser Body Sculpting Institute, Attitude Med Spa, Advanced Health, and, of course, Dynamic Stem Cell Therapy.

She thought there was a better way to help patients, Blake Youmans said. So, she found natural solutions to help them heal themselves.

Blake Youmans began working alongside his mother in 2004 and witnessed the benefits experienced through regenerative medicine. Following her passing in 2016, he chose to continue what his mother started at Dynamic Stem Cell Therapy.

I want to continue her legacy, he said. My mom really believed stem cell therapy was the best way to help people. Its been incredible.

The 2,500-square-foot clinic at 2551 North Green Valley Parkway in Henderson has a staff of six. It has grown significantly over the years strictly using reputation marketing.

Right now, I have almost 100 reviews on Google, Blake Youmans said. Out of those 100 reviews, theyre mostly five stars, so I take great pride in that because, at the end of the day, all I care about is good patient outcomes.

Dr. Dale Carrison, DO, FACEP, FACOEP is Dynamics medical director. He served at several of the valleys prestigious medical organizations, and most recently as director and chairman of the Department of Emergency Medicine at University Medical Center (UMC).

He has a great reputation in town, Blake Youmans said. I feel very blessed to have him as my medical director.

Carrison came on staff after experiencing regenerative stem cell therapy himself. His procedure performed at Dynamic involved having his own stem cells injected into his ankles.

He said it felt like he was walking on glass, Blake Youmans said about Carrisons injury. He got the procedure done and four months later his ankles felt great.

Now, he comes from a better place of empathy for patients, Blake Youmans continued. When hes doing consults, he can say how it went for him.

Blake Youmans plans to expand into other markets once things start opening back up from the pandemic.

My mothers vision was to help as many people as she could, he said. I can only do so much in Las Vegas, so I would like to go into other markets to help more people.

Members of the editorial and news staff of the Las Vegas Review-Journal were not involved in the creation of this content.

More here:

Dynamic Stem Cell Therapy Offers Regenerative Medicine - Las Vegas Review-Journal

Read more
Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I – PharmiWeb.com

A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including,

The FMI study finds that growth factor drugs continued to garner highest revenues in thechemotherapy-induced myelosuppression treatment market. In 2018, over 73% of the chemotherapy-induced myelosuppression treatment market revenues were consolidated in the growth factors. Gains were especially notable for granulocyte-colony stimulating factor or G-CSF, which accounted for over 60% of the global chemotherapy-induced myelosuppression treatment market revenues in 2018.

The FMI study reveals that erythropoietin-stimulating agents (ESA) also accounted for a significant market share, with revenues likely to grow at 2.8% in 2019. In April 2017, FDA announced the removal of risk evaluation and mitigation strategy (REMS) requirement for the use of ESA drugs in myelosuppression treatment. The ESAs used in the treatment of radiation-induced myelosuppression treatment are epoetin alfa and darbepoetin alfa. This has led healthcare professionals to engage in the practice of discussing benefits as well as risks of treatments that include ESAs before initiating the use.

A sample of this report is available upon request @https://www.futuremarketinsights.com/reports/sample/rep-gb-1364

Hematopoietic growth factors have transformed the practice of cancer treatment by allowing stimulation of production of specific cells. With this, use of thrombopoietin receptor agonists is expected to rise rapidly at the rate of 3.5% in 2019.

Injectable Drugs Present Higher Therapeutic Availability over Orals

The FMI study finds that injectable drugs accounted for over 97% of the chemotherapy-induced myelosuppression treatment market revenues in 2018. The status-quo will continue in the future, however, the oral route of administration is expected to garner increasing annual revenues and expected to grow at 4.8% in 2019 over 2018.

Increasing number of research validations related to the benefits of the oral route of administration can be attributed to the higher growth rate of the segment in the future. However, revenues from the injectable route of the administration continue to grow steadily on the back of their higher therapeutic availability over orally administered drugs.

Market Revenues Consolidated in Neutropenia Treatment

According to the study, chemotherapy-induced myelosuppression treatment market revenues heavily consolidated in the neutropenia treatment. In 2018, neutropenia indication accounted for over 62% of market revenues. As neutropenia is one of the most common side effects of chemotherapy wherein prolongation of the same can lead to life-threatening infections. Owing to the severity of the implications, chemotherapy-induced myelosuppression therapeutics are heavily used in the treatment of neutropenia.

Anemia and thrombocytopenia indications also utilize chemotherapy-induced myelosuppression treatment therapeutics. The study finds that revenues in the thrombocytopenia treatment will grow at 3.7% y-o-y in 2019.

Preview Analysis On Global Chemotherapy-Induced Myelosuppression Treatment Market Segmentation byBy Drug Class (Growth Factors, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonists, Erythropoietin-stimulating Agents, Thrombopoietic Agents, Iron supplementation, Others);By Route of Administration (Oral, Injectable);By Indication (Anemia, Neutropenia, Thrombocytopenia)

Ask an Analyst @https://www.futuremarketinsights.com/ask-question/rep-gb-1364

Retail Pharmacies Most Prominent Sales Channel

The study opines that chemotherapy-induced myelosuppression treatment therapeutics sales remain higher through retail pharmacies. Suppliers of these therapeutics have extensive distribution network with international retail pharmacies. Due to this, retail pharmacies accounted for over 48% of the chemotherapy-induced myelosuppression treatment market revenues in 2018.

Owing to heavy integration of pharmacies in the hospitals, distribution of chemotherapy-induced myelosuppression treatment therapeutics through hospital pharmacies also account for a considerable share of the market revenues. The study finds that hospital pharmacies can be called the second largest distributor of chemotherapy-induced myelosuppression treatment therapeutics owing to their 45% of the market revenues.

US The Worlds Largest Chemotherapy-induced Myelosupression Treatment Market

FMI reveals that North America accounted for over 82% of the revenues in chemotherapy-induced myelosuppression treatment market in 2018. Presence of leading cancer therapeutics providers, significant R&D investments and established healthcare sector contribute to the bulk of market revenues. The U.S. remains the largest consumer of the chemotherapy-induced myelosuppression treatment market.

Market revenues in the APEJ region are likely to grow at higher rate owing to improving healthcare facility and growing penetration of advanced cancer care treatments. China, followed by India, accounts for the highest market revenues in APEJ owing to improving economic scenario and developing healthcare infrastructure.

Table Of Content

1. Executive Summary

2. Market Introduction

3. Chemotherapy-Induced Myelosuppression Treatment Market Opportunity Analysis

4. Market Background

5. Macroeconomic Assumptions

6. Global Economic Outlook

Request Report TOC @https://www.futuremarketinsights.com/askus/rep-gb-1364

7. Key Inclusions

8. Global Market Analysis 2013-2017 and Forecast 2018-2028

9. North America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2017 and Forecast 2018-2028

10. Latin America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2017 and Forecast 2018-2028

And So On

More from Healthcare, Pharmaceuticals and Medical Devices Market

Retinal Biologics MarketSegmentation by Drug Class (VEGF-An antagonist, TNF- inhibitor); by Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Uveitis, Others); by Distributional Channel (Institutional Sales, Retail Sales):https://www.futuremarketinsights.com/reports/retinal-biologics-market

Brain Monitoring System MarketSegmentation By Product Type (Functional Near-Infrared Spectroscopy (fNIRS), Electroencephalography (EEG) Systems, Magnetoencephalography (MEG) Systems, MRI Systems, Other Brain Monitoring Systems); By Modality (Portable/Handheld Systems, Standalone Systems); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Pediatric & Neonatal Intensive care Units):https://www.futuremarketinsights.com/reports/brain-monitoring-system-market

3D Cell Culture MarketSegmentation By Product Type (Scaffold-Free 3D Cell Culture, Scaffold-Based 3D Cell Culture); By Applications (Drug Discovery, Tissue Regeneration & Regenerative Medicines, Cancer Research, Stem Cell Technology, Others); By End User (Biotechnology and Pharmaceuticals Industries, Hospital Laboratories, Academic Research Institutes, Contract Research Organizations):https://www.futuremarketinsights.com/reports/3d-cell-culture-market

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries.FMIis headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMIs latestmarket research reportsand industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek BudholiyaUnit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,Jumeirah Lakes Towers, Dubai,United Arab EmiratesMARKET ACCESS DMCC InitiativeFor Sales Enquiries:sales@futuremarketinsights.comFor Media Enquiries:press@futuremarketinsights.com

Continue reading here:

Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I - PharmiWeb.com

Read more
AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD04, an Investigational Gene Therapy for Cystinosis – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the companys investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patients own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in patients with cystinosis. AVR-RD-04 is currently being evaluated in a Phase 1/2 clinical trial (NCT03897361) sponsored by AVROBIOs academic collaborator at the University of California, San Diego.1

"People with cystinosis must often adhere to an extremely challenging treatment regimen to manage symptoms of their disease. Despite this chronic treatment, many face a significantly shortened life expectancy and require major interventions, such as a kidney transplant, said Geoff MacKay, president and CEO of AVROBIO. This investigational gene therapy, delivered in a single dose, is designed to enable patients to endogenously produce the protein their cells need to prevent the toxic build-up of cystine in tissues throughout the body. Were pleased to receive orphan drug designation in recognition of the potential of this approach to improve on the standard of care for people living with this relentless lysosomal disorder.

The EC grants orphan drug designation to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions that impact fewer than 5 in 10,000 patients in the European Union. Orphan drug designation gives companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants and 10 years of market exclusivity following regulatory approval.

AVR-RD-04 has also received orphan drug designation in the U.S. from the Food and Drug Administration.

About Cystinosis

Cystinosis is a rare, progressive disease marked by the accumulation of cystine in cellular organelles known as lysosomes. This buildup can cause debilitating symptoms including kidney failure, corneal damage and thyroid dysfunction, often leading to a shortened lifespan. Currently, more than 90 percent of treated cystinosis patients require a kidney transplant in the second or third decade of life. The current standard of care for cystinosis is cysteamine, a burdensome treatment regimen that can require dozens of pills per day and may not prevent overall progression of the disease.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statement

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as aims, anticipates, believes, could, designed to, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will, and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our prospective product candidates, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, and product approvals, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, and the expected benefits and results of our implementation of the plato platform in our clinical trials and gene therapy programs, including the use of a personalized and ultra-precision busulfan conditioning regimen. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIOs current expectations, estimates and projections about our industry as well as managements current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIOs product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIOs product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIOs actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled Risk Factors in AVROBIOs most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in AVROBIOs subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

1 Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded in part by grants to UCSD from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH).

Read the rest here:

AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD04, an Investigational Gene Therapy for Cystinosis - Business Wire

Read more
5 Health Benefits of Artichokes, According to a Nutritionist – Health.com

5 Health Benefits of Artichokes, According to a Nutritionist | Health.com Skip to content Top Navigation Close View image

5 Health Benefits of Artichokes, According to a Nutritionist

this link is to an external site that may or may not meet accessibility guidelines.

See the original post here:

5 Health Benefits of Artichokes, According to a Nutritionist - Health.com

Read more
Be The Match BioTherapies Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of…

MINNEAPOLIS--(BUSINESS WIRE)--Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership with Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to include supply chain services in support of the upcoming commercial launch of Libmeldy (autologous CD34+ cells encoding the ARSA gene), Orchards gene therapy recently approved in Europe for the treatment of early-onset metachromatic leukodystrophy (MLD).

Through the expanded partnership, Be The Match BioTherapies will provide comprehensive support across the commercial supply chain for Libmeldy, including support of the onboarding and training of apheresis centers, oversight of the autologous cell collection process and delivery of both harvested cells to the manufacturing site and gene-corrected cells back to the qualified treatment center.

Orchards mission to transform the lives of people living with devastating genetic diseases like MLD is one that closely aligns with our mission at Be The Match, which is to save lives through cellular therapy, said Chris McClain, Senior Vice President, Sales and New Business Development at Be The Match BioTherapies. Leveraging our decades of experience and our far-reaching capabilities across the cell therapy supply chain, including our international network, we are well-positioned to support the commercial launch of this important new gene therapy in Europe.

Be The Match BioTherapies previously supported cell collection for Orchards clinical trials, and, through the expanded partnership, will continue to enable streamlined logistical support across each step of Libmeldys commercial development.

HSC gene therapies are personalized medicines that require precision to harvest a patients cells, transfer the cells to a lab for genetic modification and then return the gene-corrected cells back to a qualified treatment center to infuse into the patient, said Braden Parker, chief commercial officer of Orchard. As we move into the launch phase for Libmeldy in Europe, we are pleased to continue our collaboration with Be The Match BioTherapies to help enable us to maintain the efficient, high-quality supply chain necessary to deliver Libmeldy to MLD patients in need.

About Be The Match BioTherapies

Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program (NMDP)/Be The Match, and a research partnership with the CIBMTR (Center for International Blood and Marrow Transplant Research), the organization designs solutions that advance the development of cell and gene therapies across the globe.

Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry, the worlds largest and most diverse registry of more than 22 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection and transplant centers worldwide, the organization develops, onboards, trains and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses proven infrastructure consisting of regulatory compliance and managed logistics experts, as well as cell therapy supply chain case managers to successfully transport and deliver regulatory compliant life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.

For more information, visit http://www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter at @BTMBioTherapies.

About MLD and Libmeldy/OTL-200

MLD is a rare and life-threatening inherited disease of the bodys metabolic system occurring in approximately one in every 100,000 live births. MLD is caused by a mutation in the arylsulfatase-A (ARSA) gene that results in the accumulation of sulfatides in the brain and other areas of the body, including the liver, gallbladder, kidneys, and/or spleen. Over time, the nervous system is damaged, leading to neurological problems such as motor, behavioral and cognitive regression, severe spasticity and seizures. Patients with MLD gradually lose the ability to move, talk, swallow, eat and see. In its late infantile form, mortality at five years from onset is estimated at 50% and 44% at 10 years for juvenile patients.1

Libmeldy (autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human ARSA gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD.

The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability.

For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the European Medicines Agency (EMA) website.

Libmeldy is not approved outside of the European Union, UK, Iceland, Liechtenstein, and Norway. OTL-200 is an investigational therapy in the U.S.

Libmeldy was developed in partnership with the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, visit http://www.orchard-tx.com, or follow Orchard on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains certain forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, intends, projects, anticipates, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, including its plans and expectations for the commercialization of Libmeldy (OTL-200) in Europe, the therapeutic potential of Libmeldy and Orchards product candidates, and the expected benefits from Orchards partnership with Be The Match BioTherapies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, without limitation: risks relating to the Companys inability, or the inability of Be The Match BioTherapies, to support a successful commercial launch of Libmeldy. Orchard undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards annual report on Form 10-K for the year ended December 31, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

1Mahmood et al. Metachromatic Leukodystrophy: A Case of Triplets with the Late Infantile Variant and a Systematic Review of the Literature. Journal of Child Neurology 2010, DOI: http://doi.org/10.1177/0883073809341669

Continued here:

Be The Match BioTherapies Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of...

Read more
Science on the Farm for Kids | AG | kmaland.com – KMAland

QUESTION:What would happen if you put a DNA sample from a human into another creature?

ANSWER:If were talking about a cross between a human and a Holstein cow, well thats not going to happen. But animal-human hybrid work has been going on for a number of years in labs all around the world. Thousands of animals contain human cells or deoxyribonucleic acid DNA. Most of those are mice with a single gene sequence of human origin.

There are mice with human-like livers that allow scientists to study the effects of drugs. Some lab monkeys carry a human form of the Huntingtons disease gene that permits scientists to investigate the development of that disease. There are sheep and pigs with bits of human organs growing inside them. The goal is that the animals will grow organs that can be used by humans.

Pig-heart valves have been implanted in humans for some years now. Theres hope that pig cells can be used for diabetes treatment. Fetal-pig neurons have been implanted into the brains of people with Parkinsons disease. Pig-liver cells have been used experimentally to cleanse the blood of people with liver failure, hoping to keep them alive until a donor can be found.

Stem cells have been created by inserting human genomes into rabbit eggs. Researchers have made mice with human prostate glands. Several sheep now live with a half-human liver. DNA from humans is inserted into bacteria to recreate the insulin gene; the insulin is used for many diabetic patients nationwide.

The goal of all that recombinant DNA technology research is to save lives and to study drugs and diseases. We cant use people in gruesome but necessary experiments. In stem-cell research human cells are the therapy. Under federal U.S. Food and Drug Administration rules one must test them in animals before testing them in people.

Some recent research has been truly exciting. They are doing to brain cells what they have previously done with liver and kidney cells. There are now humanized mice with Alzheimers symptoms. Neurological disorders kill 7 million people every year.

What has been described above is not the same as whole-body cloning. Cloning is the process of creating an identical copy of an organism. Dolly, a sheep, was cloned in 1996 in Scotland; she lived for six years. A cell was taken from her biological mother, transferred into the egg of a female sheep, implanted into a surrogate mother, grew into a fetus and eventually into an identical baby copy of the original animal.

Dolly was controversial and cloning is not simple. The success rate is terrible. Dolly was born after 277 eggs were used to create 29 embryos, which produced three lambs. Only one lived.

Theres talk about bringing back extinct species by cloning dead specimens and growing them in the wombs of similar animals. The Wooly Mammoth has been extinct since 1700 B.C. but the DNA of those creatures has been preserved intact in the frozen ice of the Russian tundra. That DNA transfer as well as cloning have raised serious moral and ethical issues. Consider whether we should be tampering with Mother Nature. Risks and benefits need to be looked at. Science may be ahead of rules and regulations in that area.

At KMA, we attempt to be accurate in our reporting. If you see a typo or mistake in a story, please contact us by emailing kmaradio@kmaland.com.

Larry Scheckel is the author of Seneca Seasons: A Farm Boy Remembers. He grew up on a family farm in the hill country of southwestern Wisconsin, one of nine children. His teaching career stretched to more than 38 years teaching physics and aerospace science to more than 4,000 high school students at Tomah, Wisconsin.

Continue reading here:

Science on the Farm for Kids | AG | kmaland.com - KMAland

Read more
Stem Cell Therapy Market Analysis, Industry Outlook, Current Trends and Forecast by 2025 – Just Positivity

The business intelligence report on Stem Cell Therapy market offers a comprehensive analysis of the top growth stimulants, prospects, restraints, and limitations that will shape the business dynamics in the coming years. Further, the report divides the industry vertical into several segments and systematically assesses them to unearth the top revenue prospects.

Stem Cell Therapy Market will exceed USD 15 billion by 2025; as per a new research report.

Allogenic stem cell therapy segment was valued around USD 3 billion in 2018 and is anticipated to expand substantially in near future. Allogenic transplant completely replaces host cells with donor cells. It also has the potential to eliminate viral reservoirs and genetic alterations. Therefore, allogenic stem cell therapies have been extensively utilized in providing treatment to patients suffering from leukemia and several other life threatening diseases. Thus, benefits offered by allogenic stem cell therapy will surge its demand, thereby propelling segment growth.

This report has keen to several extents of analysis - industry research (global industry trends) and Stem Cell Therapy market share analysis of topmost companies, along with company profiles, and which cooperatively include about the ultimate views regarding the Stem Cell Therapy market landscape, emerging and an evolutionary segments of Stem Cell Therapy market.

Request Sample Copy of this Report @ https://justpositivity.com/request-sample/1881

Increasing research on developing novel therapies and personalized medicines will foster stem cell therapy market growth. For instance, scientists are extensively researching on methods to regenerate healthy heart cells from placenta that can be used in patients after myocardial infarction. This discovery will help to cure patients suffering from cardiovascular diseases and reduce mortality rates. Researchers are further examining different aspects of stem cell therapy for its applications in neurological disorders. Thus, increasing R&D activities to promote developments in stem cell therapy will positively impact the industry growth.

Orthopedic segment is anticipated to witness more than 9% growth over the forecast time frame. Substantial growth is attributed to rising accidents and trauma cases across the globe. Stem cell therapy is successfully applicable in treating bone-joint injuries that include spinal and fractured bone defects, ligament tendon, femoral head and osteogenesis imperfecta. Mesenchymal stem cell therapy is preferred in curing orthopedic diseases such as arthritis and osteoporosis due to its ability to differentiate into bones and cartilage. Above mentioned factors will surge segment growth.

Rising geriatric population will positively influence the industry growth in coming years. Elderly people are susceptible to degenerative diseases such as Parkinson?s and Alzheimer?s disorders. Stem cell therapies offer several benefits over the conventional therapeutic methods that raises its preference for curing degenerative diseases. Recently developed stem cell therapies generate healthy cells by replacing the defective cells through minimally invasive techniques. Therefore, geriatric population rely on stem cell therapies that proves beneficial for the industry growth.

Major Highlights from Table of contents are listed below for quick lookup into Stem Cell Therapy Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Stem Cell Therapy industryInsights

Request Customization on This Report @ https://justpositivity.com/request-for-customization/1881

Read the original post:

Stem Cell Therapy Market Analysis, Industry Outlook, Current Trends and Forecast by 2025 - Just Positivity

Read more
Bok Choy: Nutrition, Calories, Benefits, Risks, and How to Eat It – Healthline

Bok choy is a variety of Chinese white cabbage that falls into the cruciferous vegetable category along with kale, Brussels sprouts, and broccoli.

Also called pak choi, its part of the Brassica genus of plants and is native to China. In fact, within China, its the most widely eaten brassica vegetable. However, people consume it worldwide (1).

You may be aware that cruciferous vegetables can be a key part of a healthy diet. However, you might be wondering what exactly bok choy has to offer.

This article discusses the health benefits and potential downsides to eating bok choy, and suggests a few ways to incorporate it into your diet.

Similar to other leafy greens and cruciferous vegetables, bok choy is full of health-promoting nutrients, including a wide array of vitamins and minerals.

One cup (70 grams) of shredded bok choy has the following nutritional profile (2):

Bok choy is an especially good source of vitamins C and K. It also contains some fiber, a critical nutrient found only in plant foods. Fiber supports digestive health and helps reduce the risk of many chronic diseases (3, 4, 5).

Bok choy contains a wide variety of vitamins and minerals. Its particularly high in vitamins C and K. It also offers some fiber, an important nutrient for overall health.

Many of the health benefits that bok choy offers have to do with its micronutrient content.

Bok choy is also rich in antioxidants, which are compounds that protect your cells from oxidative damage that can lead to inflammation and various chronic diseases. Vitamin C is one of the many antioxidants in bok choy (6, 7, 8).

Scientists have studied the cruciferous vegetable family for its potential anticancer benefits. These effects appear to come from their sulfur-containing compounds, called glucosinolates, and their breakdown products, called isothiocyanates (9).

One study found that eating bok choy at least once per week was associated with a significantly lower risk of oral, esophageal, colorectal, breast, and kidney cancers, compared with never or occasionally consuming bok choy (10).

Additionally, bok choy is a rich source of the mineral selenium, which may also have anticancer benefits.

In one analysis of studies, researchers found that high selenium exposure, indicated by levels in the blood or toenails, was related to a lower risk of cancers of the breast, lungs, esophagus, stomach, and prostate (11).

Another analysis of studies concluded that high intake of cruciferous vegetables, like bok choy, was associated with a lower risk of stomach cancer (12).

The selenium in bok choy is beneficial for properly functioning thyroid glands. These glands are located at the front base of your neck and play a critical role in metabolism and growth.

One study found that having a low level of selenium in the bloodstream was associated with thyroid conditions, such as hypothyroidism, autoimmune thyroiditis, and enlarged thyroid, also called goiter (13).

One study found that taking selenium supplements also helped manage these conditions (14).

A number of minerals in bok choy work to maintain bone health. These include calcium, phosphorus, zinc, magnesium, and vitamin K.

Zinc and iron play a role in collagen synthesis and vitamin D metabolism. Collagen is a type of protein that forms a matrix in your joints and skeletal system, helping maintain bone structure and strength (15, 16).

Studies have found that reduced levels of these minerals are associated with collagen reduction and an increased risk of osteoporosis, a disease in which bones soften and become prone to fracture (15, 16).

Bok choy contains the minerals potassium, magnesium, and calcium, which work to help naturally regulate your blood pressure (17).

Having unmanaged high blood pressure can be a risk factor for developing heart disease (18).

Bok choy is also a good source of folate and vitamin B6. Studies have found these may prevent the buildup of homocysteine. This compound can damage blood vessels and increase the risk of heart disease and stroke if it accumulates (19, 20, 21).

Bok choy is rich in vitamins, minerals, and antioxidants that may offer benefits for thyroid function and heart and bone health. They may even have anticancer properties.

While bok choy offers a number of health benefits, it may also come with downsides for some people when consumed in large amounts.

In their raw, uncooked form, cruciferous vegetables contain an enzyme called myrosinase that breaks down the glucosinolates that these vegetables also contain (22).

Some of the breakdown products of glucosinolates may inhibit your body from absorbing iodine, which is critical for thyroid function (22).

In one case study, an older woman was hospitalized in intensive care for severe hypothyroidism and related coma. She had been eating 1421 cups (1,0001,500 grams) of raw bok choy daily for several months (22).

Though this effect may seem severe, keep in mind this is a single, extreme case. This effect may really only be a concern if you eat an unusually large amount of raw cruciferous vegetables over an extended period.

One review notes that there is little research on the potential thyroid-inhibiting effect of bok choy. However, the researchers state that typical serving sizes of bok choy probably do not impair thyroid function (1).

Furthermore, cooking bok choy deactivates the enzyme myrosinase, so thyroid inhibition isnt a concern with cooked bok choy (23).

Additionally, because bok choy is a rich source of vitamin K, you may not want to consume it in larger amounts if you take blood thinning medication.

Significant changes in your vitamin K intake can interfere with the effectiveness of these medications. This is because vitamin K plays a role in blood clotting (24).

A 1-cup (70-gram) serving of loosely packed, chopped bok choy provides about 27% of your daily vitamin K needs (2).

If you are taking blood clotting medications, such as warfarin, you can ask your healthcare provider how much bok choy is safe to consume.

One case study suggests that eating bok choy raw in very large amounts may interfere with thyroid function, but this is probably not a concern with typical serving sizes. If you take blood thinning medication, you may want to watch your intake.

People often cook bok choy in stir-fries and soups, particularly in Asian cuisine.

You can consume all parts of the bok choy plant, including its white stems and green leaves.

Here are some ideas for how to prepare and eat bok choy:

There are plenty of ways to try adding bok choy to your diet.

You can consume bok choy raw, roasted, or cooked on the stovetop in a soup, stir-fry, or fried rice dish. You can incorporate bok choy into your diet in Asian dishes and many other ways.

Bok choy is a cruciferous, leafy green vegetable native to China. People often use it in Asian cuisine.

It offers a wide variety of vitamins and minerals, as well antioxidants and fiber that are good for your health. In fact, bok choy may be beneficial for heart health, bone health, and thyroid function. It may even have anticancer properties.

You may want to eat it in cooked form to reduce your intake of myrosinase, a compound that could interfere with iodine absorption. That said, this may only be an issue if you consume bok choy raw in large amounts. Eating bok choy in typical serving sizes is generally not a concern.

Boy choy is also high in vitamin K, so you may want to eat less or avoid it if you take blood thinning medications. If you are concerned about this, ask your healthcare provider for guidance.

You can use boy choy in a number of ways, such as raw in a salad, cooked in soup, or added to a stir-fry or fried rice dish.

More:

Bok Choy: Nutrition, Calories, Benefits, Risks, and How to Eat It - Healthline

Read more
How Will Global Stem Cell Banking Market React from 2021 Onwards? The Courier – The Courier

A recent Market Research Report byMarket Research Store, on Stem Cell Banking Market Overview By Trends, Size, Industry Top Manufacturers, Industry Growth Analysis & Forecast Till 2026 Flourishing data has been added to the collection to provide readers with detailed information about market developments, includes detailed market overview, seller scenario, market dimensions, as well as depth SWOT and PESTEL valuation, aside from other internationally approved market evaluation guidelines that play vital roles in growth of spreading information.

The report Stem Cell Banking Market 2020-2026, outlines and describes the key factors influencing market growth. It proposes an in-depth study of market heights (revenue), key market segment, market share, specific geographical regions, key market players and trends in vital industries. The purpose of this report is to describe the upcoming market trends and earnings forecasts in the global Stem Cell Banking market for the next five years.

We Have New Updates Of Stem Cell Banking Market In Sample Copy@https://www.marketresearchstore.com/report/global-stem-cell-banking-market-report-2020-industry-762536#RequestSample

(A free sample of this report is immediately available upon request and is updated with the addition of new research).

What Benefits Does Market Research Store Research Study Is Going To Provide?

The Pre & Post Impact of COVID- 19 on Businesses.2021 Latest industry influencing trends and development scenarioTake advantage of powerful market opportunitiesImportant decisions in planning and market expansionIdentify essential Business Segments, Market proposition & Gap AnalysisHelping in allocating marketing investmentsMRS Research Methodology

Stem Cell Banking Market By Top Manufacturers (2021-2026)

Boyalife, StemCyte, Crioestaminal, Esperite, Americord, Cryo-cell, PBKM FamiCord, Beikebiotech, PacifiCord, RMS Regrow, Stemade Biotech, Krio, CCBC, Cordlife Group, Cellsafe Biotech Group, Vcanbio, Familycord, ViaCord, Cells4life, LifeCell, CBR, Cryo Stemcell

Request A Free PDF Brochure: To Get An Additional List Of Dominant Market Players Included In This Report:https://www.marketresearchstore.com/report/global-stem-cell-banking-market-report-2020-industry-762536#RequestSample

Major Product Types Covered Are:

Placental Stem Cells (PSCs), Human Embryo-derived Stem Cells (HESCs), Bone Marrow-derived Stem Cells (BMSCs), Adipose Tissue-derived Stem Cells (ADSCs), Dental Pulp-derived Stem Cells (DPSCs), Other Stem Cell Sources

Major Applications of Stem Cell Banking Covered Are:

Personalized Banking Applications, Clinical Applications, Hematopoietic Disorders, Autoimmune Disorders, Other Diseases, Research Applications, Disease Treatment Studies, Life Science Research, Drug Discovery

On Some Of The Below Factors Market Player Analysis Is Based

COVID-19 Pre & Post Impact Analysis on Manufacturers profit, Revenue, and Sales.Company OverviewPrice, sales, revenue and Gross Margin AnalysisProduct portfolioRecent initiativesShare Analysis and Market Size

Lockdowns due to COVID-19 has affected economies and industries in various countries, also the businesses shutdowns and travel bans. Due to COVID-19 the decrease in the overall market growth is also affecting the Post growth of theStem Cell Banking marketowing to the shutting down of factories, lots of obstacles in the supply chain, and a downturn in the world economy.

This report presents a complete overview, growth opportunities and market shares of Stem Cell Banking market by product type, key manufacturers, application and key regions and countries. In addition, the report discusses key producers, market developments, opportunities, challenges, and factors affecting large producers and the risks facing by the whole Stem Cell Banking market. It also analyze essential emerging trends and their effect on present and future developments.

Get Free Analysis Report Of Covid-19 Impact On Stem Cell Banking Market:https://www.marketresearchstore.com/report/global-stem-cell-banking-market-report-2020-industry-762536#InquiryForBuying

Points Covered In The Report

The points discussed in the report are the vital market players that are involved in the market such as raw material suppliers, equipment suppliers, traders, end users distributors, etc.

The detailed profile of the companies is mentioned. And the capacity, production, capacity, cost, revenue, gross margin, sales volume, price, consumption, growth rate, future strategies, import, export, supply, and the technological developments that they are making are also included in the report. 12 years of data history and forecast is analyzed in this report.

The growth factors of the market are discussed where the different users of the market are described in detail.

According to specific requirements data and information by market player, by region, by type, by application, etc., and custom research can be added.

The SWOT analysis of the market within the report. The final of the report contains conclusion part where the industrial experts opinions are included.

Stem Cell Banking Market

The market research report also offers information about strategic growth market analysis, potential investment opportunities, and Potential risks that clients will follow to design business and business models and strategies. The essential data analysis in the Stem Cell Banking market report is provided in an upright way. This means that the information is represent in the form of statistics, infographics and uncomplicated graphs to make it more easier and time-saving task for the client.

The scope of Stem Cell Banking Market size reports range from broader market scenarios to comparative prices between key players, costs, and benefits of specific market segments. The numerical data is supported by statistical tools such as SWOT analysis, SCOT analysis, BCG matrix, and PESTLE analysis. The facts and figures are shown in graphical form in a clear picture.

Stem Cell Banking The report provides detailed information about the market and the strategic developments of various vital sellers. To know about the competitive landscape of the Stem Cell Banking market, an analysis of Porters five forces model is done.The study involves market attrition analysis with specific types, source types, and application segments based on market size, growth rate, and attrition.

Key strategic developments in theStem Cell Banking marketcompetitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other significant activities by key players of the Stem Cell Banking market are well described in the report.

Customization Service Of The Report:

(*Please let us knowif any special requirements about this report, we can provide a custom report..*)

Table Of Contents

Executive SummaryResearch MethodologyAssumptions and Acronyms UsedMarket OverviewGlobal Market Analysis and Forecast, by ApplicationsGlobal Market Analysis and Forecast, by TypesGlobal Market Analysis and Forecast, by RegionsLatin America Market Analysis and ForecastNorth America Market Analysis and ForecastAsia Pacific Market Analysis and ForecastThe Middle East & Africa Market Analysis and ForecastEurope Market Analysis and ForecastCompetition Landscape

Research Coverage:

The Stem Cell Banking market has been segmented based on offering, technology, end-use application, and end-user. It also provides a complete view of the market across four main regions: North America, Europe, APAC, and RoW.

About Us

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

See more here:

How Will Global Stem Cell Banking Market React from 2021 Onwards? The Courier - The Courier

Read more